膈下逐瘀汤加减治疗慢性乙型肝炎肝纤维化60例临床观察

Clinical Observation on Modified Gexia Zhuyu decoction in the Treatment of Liver Fibrosis in Chronic Hepatitis B 60 cases

目的对比中药汤剂膈下逐瘀汤加减方与中药制剂鳖甲软肝片在慢性乙型肝炎肝纤维化上的不同治疗效果。方法选取本院于2014年1月—2017年1月期间收治的60例慢性乙型肝炎肝纤维化患者,按照其使用的不同治疗方法将其分入2组,分别为使用的30例对照组患者与使用中药汤剂膈下逐瘀汤的30例研究组患者。为2组患者进行治疗效果、HBe Ag转阴率、HBV-DNA转阴率、ALT复常率的对比。结果研究组的ALT复常率为56.67%、HBV-DNA转阴率为36.67%、HBe Ag转阴率为26.67%,对照组的ALT复常率为26.67%、HBV-DNA转阴率为10.00%、HBe Ag转阴率为6.67%,研究组均优于对照组,差异有统计学意义(P<0.05)。并且,治疗后研究组的肝纤维化四项也均低于对照组,差异有统计学意义(P<0.05)。结论相较于阿德福韦酯,膈下逐瘀汤加减方对慢性乙型肝炎肝纤维化具有更好的治疗效果,其可以有效改善患者肝功能,更有效地抗肝纤维化。

Objective Comparison of different decoction of traditional Chinese medicine decoction of Xiaxia Zhuyu decoction and traditional Chinese medicine Biejia Ruangan tablet in the treatment of chronic hepatitis B liver fibrosis was made. Methods Sixty patients with chronic hepatitis B liver fibrosis who were treated in our hospital from January 2014 to January 2017 were divided into two groups according to the different treatment methods. 30 patients in the control group used Biejia Ruangan tablet. Chinese medicine decoction Gexia Zhuyu was used in the study group of 30 cases. The therapeutic effect,HBe Ag negative rate,HBV-DNA negative rate,ALT normalization rate between the two groups was compared. Results In the study group,the ALT normalization rate was 56. 67%,the negative rate of HBV DNA was36. 67%,and the negative rate of HBe Ag was 26. 67%. In the control group,the ALT normalization rate was 26. 67%,the DNA negative rate was 10. 00%,HBe Ag negative rate was 6. 67%. The study group were better than the control group,and the difference was statistically significant（ P〈0. 05）. After treatment,the four hepatic fibrosis in the study group was lower than those in the control group,and the difference was statistically significant（ P〈0. 05）. Conclusion Comparing with adefovir dipivoxil,Gexia Zhuyu decoction has better therapeutic effect in treating liver fibrosis of chronic hepatitis B,can effectively improve the liver function of patients,and more effectively resist liver fibrosis.